
To evaluate the anti‐tumor activity and the safety of anti‐PD‐1 antibody plus EGFR blockade combined with platinum‐based chemotherapy (PEP) as first‐line therapy for stage IV PSCC. PEP showed promising anti‐tumor activity, acceptable toxicity, and satisfying long‐term survival for stage IV PSCC. However, larger clinical trials are needed to validate the present study findings.
Like
Save
Share